Letter: Hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 2, 2016, Pages 210-211

  Chen, Y C ^a   Liaw, Y F ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

AGE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; HEPATITIS B; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC); VIREMIA; CHRONIC HEPATITIS B; GENETICS; HEPATITIS B VIRUS; LIVER TUMOR;

CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS;

EID: 84974733674     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13674     Document Type: Letter

References (10)

1. Gounder PP, Bulkow LR, Snowball M, et al,. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther 2016; 43: 1197-207.
2. Chen YC, Sheen IS, Chu CM, Liaw YF,. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 1084-9.
3. Yuen MF, Wong DK, Fung J, et al,. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-9.
4. Arase Y, Ikeda K, Suzuki F, et al,. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006; 119: 71. e9-e16.
5. Liu F, Wang XW, Chen L, Hu P, Ren H, Hu HD,. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther 2016; 43: 1253-61.
6. Hosaka T, Suzuki F, Kobayashi M, et al,. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
7. Chen YC, Peng CY, Jeng WJ, Chien RN, Liaw YF,. Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis. Aliment Pharmacol Ther 2015; 42: 1182-91.
8. Chen YC, Jeng WJ, Chien RN, Chu CM, Liaw YF,. Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection. Aliment Pharmacol Ther 2016; 43: 1311-18.
9. Chu CM, Liaw YF,. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010; 15: 133-43.
10. Simonetti J, Bulkow L, McMahon BJ, et al,. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010; 51: 1531-7.